ClinicalTrials.gg
Enrolling by invitationNCT05371470Updated Mar 19, 2026

Voice Analysis Technology to Detect and Manage Depression and Anxiety in Cardiac Rehabilitation

An interventional study of Ellipsis Health Voice Application in Myocardial Infarction, sponsored by Mayo Clinic. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Myocardial Infarction by Mayo Clinic — 5 open to participants now, 6 under way, none of them phase 3. Myocardial Infarction · Mayo Clinic.

Planned enrollment
3rd of 11
200 · median 107
Started
2023
the only one that year
No phase
7 of 19
3 open now
Registered
18th of 19
by date

Among the 19 studies in Myocardial Infarction by Mayo Clinic, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2023, is one of 7 with no phase, and was the 18th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

5 of the 19 studies in Myocardial Infarction by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Myocardial Infarction by Mayo Clinic, or all of them as a file.
02

Study summary

The purpose of this study is to learn if a voice analysis smartphone app which detects anxiety and depression could be used along with cardiac rehabilitation to improve results compared to cardiac rehabilitation alone.

03

Conditions studied

  • Myocardial Infarction

Keywords

  • Cardiac Rehabilitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years
  2. Enrolled in cardiac rehabilitation program to start within 3 months from hospital discharge
  3. Owns a smartphone
  4. Willing to download and use a smartphone app
  5. Able to read, write, and speak English

Exclusion criteria

Exclusion Criteria:

  1. Cardiac transplant
  2. Active substance use
  3. Neurocognitive disorder
  4. Active psychosis
  5. Mania diagnosis
  6. Active suicidality
  7. Uncontrolled bipolar disorder
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Cardiac rehabilitation plus voice analysis

    Subjects will complete 12 weeks of cardiac rehabilitation as per clinical care and utilize a voice analysis smartphone app.

    Device: Ellipsis Health Voice Application

  • No intervention
    Cardiac rehabilitation only

    Subjects will complete 12 weeks of cardiac rehabilitation as per clinical care.

Interventions

  • DeviceEllipsis Health Voice Application

    Smartphone application that utilizes voice biomarkers to assess for potential presence and severity of depression and anxiety

06

What researchers measure

Primary outcomes

  1. Change in depressive symptoms

    Measured using the self-reported Patient Health Questionnaire-9 (PHQ-9) to assess for major depressive disorder. Possible score range from 0 to 27, with higher scores indicating a worse outcome/greater severity of depressive symptoms.

    Time frame: Baseline, 12 weeks

  2. Change in anxiety symptoms

    Measured using the self-reported Generalized Anxiety Disorder 7-Item Scale (GAD-7) that assesses anxiety symptoms. Possible score range from 0 to 21, with higher scores indicating a worse outcome/greater severity of anxiety symptoms.

    Time frame: Baseline, 12 weeks

  3. Change in perceived stress

    Measured using the self-reported Perceived Stress Scale-14 (PSS-14), a 14 item questionnaire which assesses the degree to which situations in life are stressful within the last month. Each item is scored on a 5 point Likert scale from 0 (never) to 4 (very often), higher total scores indicate a worse outcome/greater severity of perceived stress.

    Time frame: Baseline, 12 weeks

  4. Change in quality of life

    Measured using the self-reported abbreviated generic Quality of Life Scale developed through the World Health Organization (WHOQOL-BREF) questionnaire that assesses an individual's perceptions of their health and well-being within the last two weeks. Each item is scored on a 5 point Likert scale, higher scores indicate greater perceived quality of life.

    Time frame: Baseline, 12 weeks

  5. Change in health behaviors

    Measured using the self-reported Current Health Behaviors (HB) questionnaire, a 13 item questionnaire which assesses behaviors and life circumstances during the last month. Each item is scored on a 10 point Likert scale, higher scores indicate better outcome.

    Time frame: Baseline, 12 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Nov 2026, 38 months after the start.

Of 322 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 38 months is close to that.

Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2022
First posted
May 12, 2022
StartActual
Sep 21, 2023
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05371470
Lead sponsor
Mayo Clinic
Responsible party
Virend Somers, MD, PhD (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
May 12, 2022
Start date
Sep 21, 2023
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Mar 19, 2026

Study contacts

Virend Somers, MD, PhD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion